Evidence map›Paper›PMID 39198804›Full record

ArticleBMC cancer2024

Mortality risk of patients with intestinal obstruction.

Yuanyuan Wang, Wei Li, Chuan-Min Zhou, Zifeng Zhao, Jianwei Ma, Haibo Jiang, Ming Wei, Yingchao Gao, Yongjun Dai, Xing Zhang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Postoperative multiple perforations of the small bowel in a patient with COVID-19 - case report.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yuanyuan Wang *Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Wei Li *Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Chuan-Min Zhou *Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Zifeng Zhao *Gastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Jianwei MaGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Haibo JiangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Ming WeiGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Yingchao GaoGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Yongjun DaiGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Xing ZhangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Ning YangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Feng FengGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Jian ZhangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Yiding JiGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Jianjie LiuGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Chao ZhangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Like LiGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Xia JiangGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China.
Zhongxin LiGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China. lizhongxin99@163.com.
Zengren ZhaoGastrointestinal Disease Diagnosis and Treatment Center, The First Hospital of Hebei Medical University, Hebei, China. zhaozengren@hebmu.edu.cn.

Funding

2022 & 2023 Hebei introduction of Foreign Expert Intelligence Projects No. YZ202201 & YZ202305Construction Funds of Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment from The First Hospital of Hebei Medical University 02-000497National Natural Science Foundation of China U23A20432Natural Science Foundation of Hebei H2021206306PI Team Supporting Fund of the First Hospital of Hebei Medical University 03000191Science Fund for Distinguished Young Scholars of Hebei Province H2023206290Shijiazhuang Municipal Government Funded the Training of Clinical Medical Talents ZF2023031
6 · The paper itself

Abstract

backgroundIntestinal obstruction represents a severe intestinal disease associated with higher mortality rates. However, the determinants of mortality in patients with intestinal obstruction remain inadequately understood. This study sought to elucidate the potential risk factors associated with mortality in the context of intestinal obstruction during the COVID-19 pandemic.

methodsA retrospective analysis was performed on a cohort of 227 patients diagnosed with intestinal obstruction at the First Hospital of Hebei Medical University, spanning the period from September 7, 2022, to January 7, 2023. The primary endpoint of the study was mortality within four weeks following discharge. Univariate and multivariable logistic regression models were utilized to evaluate the risk factors associated with mortality outcomes.

resultsA cohort of 227 patients diagnosed with intestinal obstruction (median age, 59.02 years [IQR, 48.95-70.85 years]) was included in our study. Malignant bowel obstruction (MBO) and COVID-19 were identified as independent risk factors for mortality among these patients. Notably, the mortality rate increased significantly to 38.46% when MBO was concomitant with COVID-19. Furthermore, postoperative pulmonary complications (PPC) (OR, 54.21 [death]; 95% CI, 3.17-926.31), gastric cancer (OR, 9.71 [death]; 95% CI, 1.38-68.18), VTE (Caprini Score ≥ 5) (OR, 7.64 [death]; 95% CI, 1.37-42.51), and COVID-19 (OR, 5.72 [death]; 95% CI, 1.01-32.29) were all determined to be independent risk factors for postoperative mortality. Additionally, gastric cancer could have emerged as one of the most severe risk factors for mortality in individuals with intestinal obstruction within the cohort of cancer patients, of which gastric cancer exhibited higher mortality rates compared to individuals with other forms of cancer.

conclusionThe study identifies MBO, gastric cancer, COVID-19, PPC, and VTE as potential risk factors for mortality in cases of intestinal obstruction. These findings highlight the necessity for continuous monitoring of indicators related to these mortality risk factors and their associated complications, thereby offering valuable insights for the management and treatment of intestinal obstruction.

Indexed as

COVID-19Intestinal ObstructionAgedFemaleHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesRisk FactorsSARS-CoV-2Stomach NeoplasmsAnd VTECOVID-19Gastric cancerIntestinal obstructionPostoperative pulmonary complicationRisk factorSurgery

Identifiers

PMID39198804
PMCPMC11351352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.